

Special Issue

Recent Advances in Mucosal Vaccines

Message from the Guest Editor

Dear colleagues, Without doubt vaccines for humans and animals have saved millions from the devastating effects of infectious diseases. Despite this success, there is an urgent need to develop novel and improved vaccines to further reduce the global burden of morbidity and mortality related to infectious diseases. Most pathogens infect the host via or at the mucosal surfaces and a robust mucosal immunity is required to prevent pathogens from gaining a foothold on these surfaces. The majority of current licensed vaccines are however injectables, which mostly fail to elicit robust mucosal immune responses. Mucosal vaccines might surmount this limitation of injected vaccines, but their development is challenging due to the intrinsic nature of the mucosal surfaces to degrade antigens and prevent vaccine uptake as well as the inherent tolerogenic responses of the mucosal immune system. The scope of this special issue concerns recent advances in vaccine design, including formulation, delivery systems and adjuvant technology, to overcome these hurdles in triggering protective immunity at mucosal surfaces.

Guest Editor

Dr. Bert Devriendt

Laboratory of Immunology, Department of Virology, Parasitology and Immunology, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium

Deadline for manuscript submissions

closed (31 March 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/41194

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).